NCT02152605 - A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

498

Participants

Timeline

Start Date

September 1, 2014

Primary Completion Date

March 1, 2015

Study Completion Date

March 5, 2015

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

UMEC/VI

Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg

DRUG

Placebo

Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo

Trial Locations (54)

1085

GSK Investigational Site, Budapest

1336

GSK Investigational Site, Sofia

2040

GSK Investigational Site, Budaörs

2100

GSK Investigational Site, Gödöllő

2500

GSK Investigational Site, Kyustendil

2600

GSK Investigational Site, Dupnitsa

2660

GSK Investigational Site, Balassagyarmat

3800

GSK Investigational Site, Szikszó

4032

GSK Investigational Site, Debrecen

4400

GSK Investigational Site, Nyíregyháza

5300

GSK Investigational Site, Gabrovo

5400

GSK Investigational Site, Sevlievo

6722

GSK Investigational Site, Szeged

8800

GSK Investigational Site, Sliven

10119

GSK Investigational Site, Berlin

10629

GSK Investigational Site, Berlin

10717

GSK Investigational Site, Berlin

22143

GSK Investigational Site, Hamburg

23858

GSK Investigational Site, Reinfeld

28844

GSK Investigational Site, Weyhe-Leeste

29379

GSK Investigational Site, Union

29464

GSK Investigational Site, Mt. Pleasant

29621

GSK Investigational Site, Anderson

29640

GSK Investigational Site, Easley

29678

GSK Investigational Site, Seneca

29732

GSK Investigational Site, Rock Hill

34121

GSK Investigational Site, Kassel

61002

GSK Investigational Site, Kharkiv

61124

GSK Investigational Site, Kharkiv

63301

GSK Investigational Site, Saint Charles

78229

GSK Investigational Site, San Antonio

85006

GSK Investigational Site, Phoenix

91786

GSK Investigational Site, Upland

110084

GSK Investigational Site, Piteşti

117997

GSK Investigational Site, Moscow

194356

GSK Investigational Site, Saint Petersburg

195030

GSK Investigational Site, Saint Petesburg

197706

GSK Investigational Site, Sestroretsk

198216

GSK Investigational Site, Saint Petersburg

200642

GSK Investigational Site, Craiova

330084

GSK Investigational Site, Deva

355017

GSK Investigational Site, Stavropol

394018

GSK Investigational Site, Voronezh

400371

GSK Investigational Site, Cluj-Napoca

432063

GSK Investigational Site, Ulyanovsk

505100

GSK Investigational Site, Codlea

620039

GSK Investigational Site, Yekaterinburg

630099

GSK Investigational Site, Novosibirsk

700115

GSK Investigational Site, Iași

33765-2616

GSK Investigational Site, Clearwater

Unknown

GSK Investigational Site, Montana

03680

GSK Investigational Site, Kiev

01114

GSK Investigational Site, Kyiv

02232

GSK Investigational Site, Kyiv